Anavex Life Sciences Corp (AVXL)

[falconer66a]

Today’s revenue projections probably way too small.

After Missling’s conjecture on what a year’s treatment with blarcamesine in girls with Rett syndrome will cost (six figures), there have been a good number of postings extrapolating those numbers, in some way, on to revenues eventually from the other two Anavex CNS disease targets, Parkinson’s disease dementia, and Alzheimer’s. Well and good. But very likely all of them, in say five years or so, will prove entirely wrong.

From the company’s list of pipeline drugs and diseases, in addition to the present three CNS diseases, there are: Parkinson's Disease, Infantile Spasms, Angelman Syndrome, an undisclosed rare disease, Frontotemporal Dementia, Depression, Stroke, Visceral Pain, and Acute & Neuropathic Pain. Previously, elsewhere, there have tangential references to treatments or prevention of cardiovascular diseases and cancers.
https://www.anavex.com/therapeutic-candidates

How would corporate revenues be affected if, say, only a few of these others gain approval for the use of an Anavex drug?

But perhaps the biggest source of continuing revenues will result from the discovery that patients taking any of the Anavex drugs get relief from other geriatric diseases. People taking blarcamesine for their Alzheimer’s get relief; have normalized cognition, etc. But at the same time it’s discovered that they have far lower rates of cardiovascular disease or cancers. Consequently, blarcamesine gets prescribed as a geriatric disease prophylactic, preventative. Everyone, starting in their forties, starts taking one or two Anavex pills a week, for the rest of their lives.

With other new diseases, and Anavex prophylaxis, add a few more zeros to the annual revenues metric.